Marco Witkowski

Marco Witkowski

Auto-generated profile, based on publicly available information

Marco Witkowski

Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MWMarco Witkowski
Marco Witkowski
INIna Nemet
Ina Nemet
HAHassan Alamri
Hassan Alamri
JWJennifer Wilcox
Jennifer Wilcox
NGNilaksh Gupta
Nilaksh Gupta
SHStanley L. Hazen
Stanley L. Hazen

1 January 2023 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
KRKymberleigh A. Romano
Kymberleigh A. Romano
INIna Nemet
Ina Nemet
PSPrasenjit Saha
Prasenjit Saha
AHArash Haghikia
Arash Haghikia
XLXinmin Simon Li
Xinmin Simon Li
SHStanley L. Hazen
Stanley L. Hazen
Background: The gut microbiota-dependent metabolite phenylacetylgutamine (PAGln) is both associated with atherothrombotic heart disease in humans, and mechanistically linked to cardiovascular disease pathogenesis in animal models via modulation of adrenergic receptor signaling. Methods: Here we examined both clinical and mechanistic relationships between PAGln and heart failure (HF). First, we examined associations among plasma levels of PAGln and HF, left ventricular ejection fraction, and N-terminal pro-B-type natriuretic peptide in 2 independent clinical cohorts of subjects undergoing coronary angiography in tertiary referral centers (an initial discovery US Cohort, n=3256; and a validation European Cohort, n=829). Then, the impact of PAGln on cardiovascular phenotypes relevant to HF in cultured cardiomyoblasts, and in vivo were also examined. Results: Circulating PAGln levels were dose-dependently associated with HF presence and indices of severity (reduced ventricular ejection fraction, elevated N-terminal pro-B-type natriuretic peptide) independent of traditional risk factors and renal function in both cohorts. Beyond these clinical associations, mechanistic studies showed both PAGln and its murine counterpart, phenylacetylglycine, directly fostered HF-relevant phenotypes, including decreased cardiomyocyte sarcomere contraction, and B-type natriuretic peptide gene expression in both cultured cardiomyoblasts and murine atrial tissue. Conclusions: The present study reveals the gut microbial metabolite PAGln is clinically and mechanistically linked to HF presence and severity. Modulating the gut microbiome, in general, and PAGln production, in particular, may represent a potential therapeutic target for modulating HF. Registration: URL: https://clinicaltrials.gov/ ; Unique identifier: NCT00590200 and URL: https://drks.de/drks_web/ ; Unique identifier: DRKS00020915.

19 February 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MFMarc Ferrell
Marc Ferrell
Zeneng WangZeneng Wang
Zeneng Wang
JAJames T. Anderson
James T. Anderson
XLXinmin Simon Li
Xinmin Simon Li
MWMarco Witkowski
Marco Witkowski
SHStanley L. Hazen
Stanley L. Hazen

6 June 2024 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
MWMarco Witkowski
Marco Witkowski
INIna Nemet
Ina Nemet
XLXinmin Simon Li
Xinmin Simon Li
JWJennifer Wilcox
Jennifer Wilcox
MFMarc Ferrell
Marc Ferrell
SHStanley L Hazen
Stanley L Hazen
The pathways and metabolites that contribute to residual cardiovascular disease risks are unclear. Low-calorie sweeteners are widely used sugar substitutes in processed foods with presumed health benefits. Many low-calorie sweeteners are sugar alcohols that also are produced endogenously, albeit at levels over 1000-fold lower than observed following consumption as a sugar substitute. Untargeted metabolomics studies were performed on overnight fasting plasma samples in a discovery cohort (n = 1157) of sequential stable subjects undergoing elective diagnostic cardiac evaluations; subsequent stable isotope dilution liquid chromatography tandem mass spectrometry (LC-MS/MS) analyses were performed on an independent, non-overlapping validation cohort (n = 2149). Complementary isolated human platelet, platelet-rich plasma, whole blood, and animal model studies examined the effect of xylitol on platelet responsiveness and thrombus formation in vivo. Finally, an intervention study was performed to assess the effects of xylitol consumption on platelet function in healthy volunteers (n = 10). In initial untargeted metabolomics studies (discovery cohort), circulating levels of a polyol tentatively assigned as xylitol were associated with incident (3-year) major adverse cardiovascular event (MACE) risk. Subsequent stable isotope dilution LC-MS/MS analyses (validation cohort) specific for xylitol (and not its structural isomers) confirmed its association with incident MACE risk [third vs. first tertile adjusted hazard ratio (95% confidence interval), 1.57 (1.12–2.21), P < .01]. Complementary mechanistic studies showed xylitol-enhanced multiple indices of platelet reactivity and in vivo thrombosis formation at levels observed in fasting plasma. In interventional studies, consumption of a xylitol-sweetened drink markedly raised plasma levels and enhanced multiple functional measures of platelet responsiveness in all subjects. Xylitol is associated with incident MACE risk. Moreover, xylitol both enhanced platelet reactivity and thrombosis potential in vivo. Further studies examining the cardiovascular safety of xylitol are warranted. Role of the artificial sweetener xylitol in cardiovascular event risk. In initial untargeted metabolomics studies (discovery cohort) and subsequent stable isotope dilution liquid chromatography tandem mass spectrometry (LC-MS/MS) studies (validation cohort), fasting levels of xylitol are associated with incident major adverse cardiovascular events (MACE). Using human whole blood, platelet-rich plasma, and washed platelets, xylitol enhances multiple indices of platelet reactivity in vitro. Xylitol also was shown to enhance thrombosis formation in a murine arterial injury model in vivo. In human intervention studies, when subjects ingested a typical dietary amount of xylitol in an artificially sweetened food, multiple functional measures of platelet responsiveness were significantly increased. Xylitol is both clinically associated with cardiovascular event risks and mechanistically linked to enhanced platelet responsiveness and thrombosis potential in vivo. ADP, adenosine diphosphate; MI, myocardial infarction.

13 December 2021 in Cells
Verified
Journal Article
Open access
PDF file
JFJulian Friebel
Julian Friebel
EMEileen Moritz
Eileen Moritz
MWMarco Witkowski
Marco Witkowski
KJKai Jakobs
Kai Jakobs
ESElisabeth Strässler
Elisabeth Strässler
URUrsula Rauch
Ursula Rauch
Background: Protease-activated receptor 1 (PAR1) and toll-like receptors (TLRs) are inflammatory mediators contributing to atherogenesis and atherothrombosis. Vorapaxar, which selectively antagonizes PAR1-signaling, is an approved, add-on antiplatelet therapy for secondary prevention. The non-hemostatic, platelet-independent, pleiotropic effects of vorapaxar have not yet been studied. Methods and Results: Cellular targets of PAR1 signaling in the vasculature were identified in three patient cohorts with atherosclerotic disease. Evaluation of plasma biomarkers (n = 190) and gene expression in endomyocardial biopsies (EMBs) (n = 12) revealed that PAR1 expression correlated with endothelial activation and vascular inflammation. PAR1 colocalized with TLR2/4 in human carotid plaques and was associated with TLR2/4 gene transcription in EMBs. In addition, vorapaxar reduced atherosclerotic lesion size in apolipoprotein E–knock out (ApoEko) mice. This reduction was associated with reduced expression of vascular adhesion molecules and TLR2/4 presence, both in isolated murine endothelial cells and the aorta. Thrombin-induced uptake of oxLDL was augmented by additional TLR2/4 stimulation and abrogated by vorapaxar. Plaque-infiltrating pro-inflammatory cells were reduced in vorapaxar-treated ApoEko mice. A shift toward M2 macrophages paralleled a decreased transcription of pro-inflammatory cytokines and chemokines. Conclusions: PAR1 inhibition with vorapaxar may be effective in reducing residual thrombo-inflammatory event risk in patients with atherosclerosis independent of its effect on platelets.

1 September 2024 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
MWMarco Witkowski
Marco Witkowski
JWJennifer Wilcox
Jennifer Wilcox
VPValesha Province
Valesha Province
Zeneng WangZeneng Wang
Zeneng Wang
INIna Nemet
Ina Nemet
SHStanley L. Hazen
Stanley L. Hazen
BACKGROUND: Although artificial and non-nutritive sweeteners are widely used and generally recognized as safe by the US and European Union regulatory agencies, there have been no clinical trials to assess either long-term cardiovascular disease risks or short-term cardiovascular disease–relevant phenotypes. Recent studies report that fasting plasma levels of erythritol, a commonly used sweetener, are clinically associated with heightened incident cardiovascular disease risks and enhance thrombosis potential in vitro and in animal models. Effects of dietary erythritol on thrombosis phenotypes in humans have not been examined. METHODS: Using a prospective interventional study design, we tested the impact of erythritol or glucose consumption on multiple indices of stimulus-dependent platelet responsiveness in healthy volunteers (n=10 per group). Erythritol plasma levels were quantified with liquid chromatography tandem mass spectrometry. Platelet function at baseline and following erythritol or glucose ingestion was assessed via both aggregometry and analysis of granule markers released. RESULTS: Dietary erythritol (30 g), but not glucose (30 g), lead to a >1000-fold increase in erythritol plasma concentration (6480 [5930–7300] versus 3.75 [3.35–3.87] μmol/L; P <0.0001) and exhibited acute enhancement of stimulus-dependent aggregation responses in all subjects, agonists, and doses examined. Erythritol ingestion also enhanced stimulus-dependent release of the platelet dense granule marker serotonin ( P <0.0001 for TRAP6 [thrombin activator peptide 6] and P =0.004 for ADP) and the platelet α-granule marker CXCL4 (C-X-C motif ligand-4; P <0.0001 for TRAP6 and P =0.06 for ADP). In contrast, glucose ingestion triggered no significant increases in stimulus-dependent release of either serotonin or CXCL4. CONCLUSIONS: Ingestion of a typical quantity of the non-nutritive sweetener erythritol, but not glucose, enhances platelet reactivity in healthy volunteers, raising concerns that erythritol consumption may enhance thrombosis potential. Combined with recent large-scale clinical observational studies and mechanistic cell-based and animal model studies, the present findings suggest that discussion of whether erythritol should be reevaluated as a food additive with the Generally Recognized as Safe designation is warranted. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04731363.